Forget Gilead - This Tiny Biotech Offers A Much Richer Opportunity
Gilead Sciences (NASDAQ: GILD ) has been one of the most closely watched and hotly debated biotechs over the last two years following the launch of its game-changing hepatitis C franchise composed of Harvoni and Sovaldi. Its share price, though, has struggled since the launch of rival drugs late last year, shown by the chart below:
Hey, check out all the research scientist jobs. Post your resume today!
Hey, check out all the research scientist jobs. Post your resume today!